{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hse.00537:a retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Ahse.00537%3Aa",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.003818,
    "timestamp_received": "2026-04-25T12:52:12.300273+00:00Z",
    "timestamp_returned": "2026-04-25T12:52:12.304091+00:00Z",
    "trace_id": "435d8c82-9c83-4e17-bd81-87a89a634312"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:hse.00537:a",
      "indication": "Monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).",
      "initial_approval_date": "2019-05-01",
      "initial_approval_url": null,
      "description": "The Republic of Ireland's Health Service Executive (HSE) has approved inotuzumab ozogamicin for reimbursement as a monotherapy treatment option for the treatment of adult patients with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). The indication further states that adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).",
      "raw_biomarkers": null,
      "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
      "raw_therapeutics": "Inotuzumab ozogamicin",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:hse.00537",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Inotuzumab Ozogamicin Monotherapy. NCCP National SACT Regimen. HSE.",
        "title": null,
        "aliases": [],
        "description": "Inotuzumab Ozogamicin Monotherapy, 2021, version number 2, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6981/537_v2_Inotuzumab.pdf",
        "urls": [
          "https://healthservice.hse.ie/documents/6981/537_v2_Inotuzumab.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "hse",
              "type": "Agent",
              "agentType": "organization",
              "name": "Health Service Executive",
              "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://healthservice.hse.ie/staff/information-healthcare-workers/nccp/national-sact-regimens/",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": null,
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": null,
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": null,
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2021-11-19",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}